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Purpose: Cryptogenic epilepsy, defines a group of epilepsy syndromes for which an aetiology is unknown but an underly-
ing brain disease is suspected. We selected patients in this subgroup of epilepsy and investigated the sero-positivity rate for
anti-Toxoplasma IgG antibodies by Enzyme Linked Immunosorbent Assay (ELISA). We investigated the probable relationship
between Toxoplasma gondii and cryptogenic epilepsy.
Methods: We selected 50 patients with cryptogenic epilepsy, 50 patients with known cause epilepsy and 50 healthy volunteers
and investigated the sero-positivity rate for anti-Toxoplasma IgG antibodies by ELISA.
Results: The sero-positivity rate for anti-Toxoplasma IgG antibodies among cryptogenic epilepsy patients (52%) was found to
be higher than healthy volunteers (18%) and known cause epilepsy patients (22%) with statistical significance, (X2 = 18.095,
P < 0.01).
Conclusion: There might be a causal relationship between chronic toxoplasmosis and the aetiology of cryptogenic epilepsy.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Toxoplasma gondii is worldwide in distribution, is
closely related to other coccidia, and also has certain
similarities to malarial parasites. The parasites were
first discovered in the North African rodent called the
Ctenodactylus gundii, hence the species name gondii.
Although serologic evidence indicates a high rate of
human exposure to the organism, the disease itself is
relatively rare. T. gondii can infect many vertebrates
as well as humans, but the definitive host is the house
cat and other members of the Felidae family1.
This organism is an obligate intracellular parasite
and is found in two forms in humans. The actively
proliferating trophozoites or tachyzoites are usually
seen in the early, more acute phases of the infection.
The resting forms or tissue cysts are primarily found
in muscle and brain, probably as a result of the host
immune response1.
Toxoplasma infections can be acquired postnatally
and categorised into four groups:
(a) Lymphadenitis, fever, headache, and myalgia,
with a possibility of splenomegaly and a brief
erythematous rash
(b) Typhus-like exanthemaous form with myocardi-
tis, meningoencephalitis, atypical pneumonia,
and possible death
(c) Retinochoroiditis, which may be severe, requir-
ing enucleation
(d) CNS involvement, which is usually fatal2.
The large numbers of people who are serologically
positive for T. gondii suggest that the majority of in-
fections are benign, with most people exhibiting few
(e.g. coryzal or mild “flu” like illness) or no symp-
toms. Overall, approximately 2.5% of AIDS patients
have been diagnosed with cerebral toxoplasmosis.
The cryptogenic epilepsies are epilepsy syndromes
for which an aetiology is unknown, but an underlying
brain disease is suspected. They affect approximately
20% of all patients with epilepsy3. A diagnosis of
cryptogenic epilepsy cannot be made in the pres-
ence of a family history of epilepsy, a history of
head trauma, meningitis, brain surgery, an abnormal
magnetic resonance imaging (MRI) study, an abnor-
mal electroencephalogram (EEG)—such as that seen
with absence of seizures—or other inherited forms
of epilepsy and alcoholism. In the MRI era, many
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cases of cryptogenic epilepsy have been attributed
to medial temporal sclerosis or congenital, neuronal
migrational abnormalities previously undetectable by
neuroimaging techniques4.
Several parasitic infections cause convulsions, most
of which are easily detected by cerebrospinal fluid
(CSF) analysis, serum testing, and MRI4. T. gondii
can form dormant cysts in the brain, which are mi-
croscopic and undetectable with MRI or routine
CSF analysis. T. gondii in its dormant, bradycyst
form, is generally not associated with symptoms;
however, with immunosupression of the host, re-
activation of the bradizoites causes the potentially
lethal disease, toxoplasmosis5. About 20% of the
US population is sero-positive for immunoglobulin
G (IgG) for T. gondii, making this one of the most
prevalent and probably the only chronic parasitic in-
fection lasting a human lifetime without any known
consequences6. In France, the rate of sero-positivity
has been reported to reach 80%, which may be in part
explained by cultural preference for undercooked or
raw meat7. In Turkey, the rate of sero-positivity was
reported as 23.1% in I˙zmir8, and 36% in Kayseri9.
A positive antibody titre reflects the persistence of
parasites in the CNS10. Tissue cysts containing bradi-
zoites may spontaneously rupture releasing parasites
that cause antibody titres to remain elevated11. The
bradycyst form of T. gondii is a prevalent, dormant
parasitic infection in the brain and could have the
potential to cause epilepsy, as do other parasitic
infections4.
We selected patients from the cryptogenic epilepsy
subpopulation and tested them with micro enzyme-
linked immunosorbent assay (ELISA) for T. gondii an-
tibodies, under the assumption that a positive antibody
titre (IgG) reflects chronic infection and the presence
of tissue cysts within the CNS.
MATERIALS AND METHODS
Patients and their sera
In this study, 50 patients with cryptogenic epilepsy
were selected from patients who applied to Erciyes
University Medical Faculty Neurology Department
between 1999–2002. All patients had normal MRI of
the brain, no family history of epilepsy, no history
of head trauma, brain surgery, or previous meningi-
tis/encephalitis, and no history of alcoholism. We also
selected 50 patients with known cause epilepsy (13
head trauma, 12 family history of epilepsy, 9 brain
surgery, 8 previous encephalitis, 8 history of alco-
holism) and 50 healthy volunteers as control groups.
5-ml blood was taken from all patients and healthy
volunteers under sterile conditions. Blood samples
were centrifuged at 1000 rpm and sera separated and
were stored at −20 ◦C until the analysis.
Serologic technique
We used the micro ELISA technique for T. gondii.
Anti-T. gondii IgG and IgM antibodies ELISA kit pro-
vided from EUROIMMUN commercial manufacturer.
We followed the manufacturer’s instructions.
Statistic
For statistical analyses, SPSS V.9.0 for Windows
pocket programme was used.
RESULTS
In our study, IgG titers of 27 of 50 (54%) cases in the
cryptogenic epilepsy group, 11 of 50 (22%) cases in
the known cause epilepsy group and 9 of 50 (18%)
cases in the non-epileptic healthy volunteers were
tested as positive. IgM titers tested as negative in all
of the groups by ELISA (Table 1). Positive optic den-
sity (OD) values were obtained for anti-T. gondii IgG
antibody and were changed into international units
(IU) according to test procedure.
The percentage of anti T. gondii IgG positive an-
tibody in cryptogenic epilepsy patients (54%) was
found to be greater than known cause epilepsy pa-
tients (22%) and non-epileptic healthy volunteers
(18%). Thus, the results indicate a statistically sig-
nificant difference between the cryptogenic epilepsy
group and the other two groups (X2 = 18.095,
P < 0.01).
All patients and controls lived in Middle Anato-
lia, Turkey. The gender distribution of the patients
and controls were similar; 31 women and 19 men
for the cryptogenic epilepsy group, 29 women and
21 men for the known cause epilepsy group and 23
women and 27 men for the non-epileptic healthy vol-
unteers. The age distributions were also similar, with
a mean age of 37.82±16.64 years among cryptogenic
epilepsy patients, 35.78 ± 13.53 years among known
cause epilepsy patients and 34.02±13.85 years among
healthy volunteers.
Table 1: Results of anti-T. gondii antibodies analysis in
cryptogenic epilepsy patients and in control groups.
IgG (+) Total
Cryptogenic epilepsy 27 (54%) 50
Known cause epilepsy 11 (22%) 50
Healthy volunteer 9 (18%) 50
X2 = 18.095; P < 0.01.
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DISCUSSION
T. gondii is found in two different stages in humans.
The actively proliferating intracellular forms are called
trophozoites or tachyzoites and are crescent shaped.
Many different tissues may be parasitised by these
organisms, particularly lung, heart, lymphoid organ,
and CNS tissues. The resting forms or cyst stages are
found in the tissue and contain the more slowly de-
veloping bradizoites12.
Toxoplasmosis can vary from an asymptomatic,
self-limiting infection to a fatal disease, as seen in
patients with congenital infections or in debilitated
patients in whom underlying conditions may influence
the final outcome of the infection. In immunocom-
pramised patients, the infection most often involves
the nervous system, with diffuse encephalopathy,
meningoencephalitis, or cerebral mass lesions12.
Toxoplasma encephalitis (TE) has been reported
as a life-threatening opportunistic infection among
patients with AIDS. In one study of 41 AIDS pa-
tients, 47.4% of Toxoplasma sero-positive patients
developed CNS toxoplasmosis. This percentage is
considerably higher than the previously estimated
risk percentages of 12–18% for the development of
CNS involvement13. Overall, approximately 2.5%
of AIDS patients have been diagnosed with cerebral
toxoplasmosis14.
In the mouse model, there is evidence of focal in-
flammation with disrupted bradycysts15. Bradycysts
mature slowly and have been shown to eventually lyse
in the immunocompotent host, re-establishing chronic
infection, and in the process, producing microscopic
scars (glial nodules)11.
We found only one study of investigation of
anti-T. gondii antibodies by ELISA among epileptic
patients4. This study was carried out by Stommel et al.
in 2001. They identified 22 patients with cryptogenic
epilepsy and on the basis of the ELISA values, 75%
of the 22 patients had greater T. gondii antibody titers
than the median titer observed among the 23 controls.
In our study, the sero-positivity rate for anti-
Toxoplasma IgG antibodies of cryptogenic epilepsy
patients (54%), indicates chronic infection, was found
to be greater than the known cause epilepsy patients
(22%) and non-epileptic healthy volunteers (18%).
Anti-Toxoplasma IgM antibodies, indicating acute
infection, were found to be negative in all of the
groups. These results are similar and confirm the re-
sults of Stommel et al. If these results are verified
with greater number of epileptic patients by other
researchers, there may be new approaches to the
treatment of cryptogenic epilepsy.
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